Aberdeen Group
BMY.RT

Aberdeen Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Aberdeen Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-199
Closed -$1K – 969
2020
Q2 		$1K Buy
+199
New +$718 ﹤0.01% 926

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aberdeen Group's BMY.RT Position: Q3 2020 in Review

Aberdeen Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 199 shares — an estimated $1K sold.

Aberdeen Group first reported a position in BMY.RT in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Aberdeen Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Aberdeen Group sold 199 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $1K.
  • Aberdeen Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 1 quarter.
  • Aberdeen Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Aberdeen Group's 13F filing for Q3 2020, filed 21 Oct 2020.